Edesa Biotechの企業価値
Edesa Biotechの企業価値は何ですか。
Edesa Biotech, Inc.の企業価値は4.67M$です。
企業価値の定義は何ですか。
企業価値は、企業の総市場価値の尺度です。これは、負債、少数株主持分および優先株式から現金および現金同等物を差し引いた時価総額として計算されます。
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
NASDAQのセクタHealth Careにおける企業価値の企業と比べるEdesa Biotech
Edesa Biotechは何をしますか。
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Edesa Biotechと類似の企業価値
- Golden Ridge Resourcesの企業価値は4.65M$です。
- Accelerate Resourcesの企業価値は4.65M$です。
- Lodestar Mineralsの企業価値は4.66M$です。
- RooLife Ltdの企業価値は4.66M$です。
- ABC Indiaの企業価値は4.66M$です。
- Conico Ltdの企業価値は4.66M$です。
- Edesa Biotechの企業価値は4.67M$です。
- SiS Mobileの企業価値は4.67M$です。
- Tri-Star Resources Plcの企業価値は4.67M$です。
- HTC Purenergyの企業価値は4.67M$です。
- Prospect Park Capitalの企業価値は4.67M$です。
- Spinnaker Acquisitions Plcの企業価値は4.68M$です。
- EZZ Life Scienceの企業価値は4.68M$です。